lig1 deletion predicts chemotherapy resistance in triple-negative breast cancer
Published 2 years ago • 660 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
1:24
combining chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:51
optimal chemotherapy combinations in tnbc gbrca subtypes
-
0:51
challenges in the treatment of mtnbc
-
2:09
triplet combination of chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
1:04
future directions in triple-negative breast cancer research
-
2:46
de-escalation of therapy in early-stage tnbc
-
1:39
encouraging developments in triple negative breast cancer immunotherapy
-
1:13
predictive markers of response to durvalumab w/nab-paclitaxel doxorubicin/cyclophosphamide in tnbc
-
4:38
alice: atezolizumab immunogenic chemotherapy in metastatic tnbc
-
1:40
predicting pathological complete response in breast cancer
-
1:58
promising novel approaches to the treatment of tnbc
-
0:50
triple negative survivors! (listen up)
-
1:58
targeted therapy in tnbc
-
1:13
crosstalk between triple negative breast cancer and microenvironment | oncotarget
-
1:07
precision medicine for metastatic triple-negative breast cancer
-
0:10
finished chemo and still don't feel like yourself